Episode # 527 • 21 Mar 2025
Managing Hereditary Hemorrhagic Telangiectasia & Pulmonary AVMs
Targeted, image-guided interventions can make a big difference for patients with hereditary hemorrhagic telangiectasia (HHT). Learn how in this week’s BackTable episode featuring Dr. Clifford R. Weiss (Director of the Johns Hopkins Vascular Anomalies Center and HHT Center of Excellence) and host Dr. Michael Barraza.
Timestamps
00:00 - Introduction
03:57 - Diagnosing and Screening for Hereditary Hemorrhagic Telangiectasia (HHT)
07:37 - Treatment Approaches for HHT
12:12 - Embolization Techniques and Safety Measures
19:02 - Future of HHT Treatment and Research
22:30 - Conclusion and Final Thoughts
Resources
You may also like
More about this episode
Dr. Weiss delves into the complexities and multisystem nature of HHT, emphasizing the significance of early diagnosis and multidisciplinary care. He goes on to explain the clinical criteria for diagnosing HHT, the role of genetic and imaging screenings, and the evolving approaches to treating pulmonary arteriovenous malformations (AVMs) in adults and children. The doctors discuss the potential impact of anti-angiogenic medications on the future management of HHT. The episode closes with a nod to the pivotal role that HHT Centers of Excellence play, and the ongoing dedication to improving patient outcomes through collaborative care and innovative research.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.